Guselkumab for Pityriasis Rubra Pilaris and Dysregulation of IL-23/IL-17 and NFkB Signaling
Velasco R, Shao C, Cutler B, Strunck J, Kent G, Cassidy P, Choate K, Greiling T. Guselkumab for Pityriasis Rubra Pilaris and Dysregulation of IL-23/IL-17 and NFkB Signaling. JAMA Dermatology 2024, 160: 641-645. PMID: 38598229, PMCID: PMC11007649, DOI: 10.1001/jamadermatol.2024.0257.Peer-Reviewed Original ResearchPsoriasis Area Severity IndexPityriasis rubra pilarisDermatology Life Quality Index scoresInvolvement of interleukinsQuality Index scoreFood and Drug Administration-approved treatmentPrimary outcomeUS Food and Drug Administration-approved treatmentPsoriasis area severity index scoreSex-matched healthy controlsIL-23p19 inhibitorsP19 subunit of IL-23Index scoreArea Severity IndexIL-23/IL-17Subunit of IL-23Per-protocol analysisClinical responseStudy drugDosing scheduleClinical respondersClinical improvementMale patientsIL-23Guselkumab